Monoclonal antibody therapy-associated neurological disorders (Q37832130)

24 August 2017

1 reference

title

Monoclonal antibody therapy-associated neurological disorders (English)

1 reference

24 August 2017

1 reference

1 reference

2

1 reference

24 August 2017

Manuel Ramos-Casals

3

0 references

author name string

Xavier Bosch

series ordinal

1

1 reference

PubMed ID

21263460

24 August 2017

BIOGEAS Study Group

series ordinal

4

1 reference

PubMed ID

21263460

24 August 2017

language of work or name

English

0 references

publication date

25 January 2011

1 reference

24 August 2017

Nature Reviews Neurology

1 reference

24 August 2017

7

1 reference

24 August 2017

3

1 reference

24 August 2017

165-172

1 reference

https://scigraph.springernature.com/pub.10.1038/nrneurol.2011.1

24 August 2017

0 references

cites work

Monoclonal antibody therapies and neurologic disorders

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.1

Autoimmune diseases induced by TNF-targeted therapies

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.1

Acute motor and sensory axonal neuropathy and concomitant encephalopathy during tumor necrosis factor-alpha antagonist therapy.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.1

Autoimmune diseases induced by biological agents: a double-edged sword?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.1

Autoimmune Diseases Induced by TNF-Targeted Therapies

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.1

Vasculitis induced by tumor necrosis factor-targeted therapies

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.1

Progressive multifocal leukoencephalopathy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.1

Progressive multifocal leukoencephalopathy: can we reduce risk in patients receiving biological immunomodulatory therapies?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.1

Monoclonal antibodies in MS: mechanisms of action

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.1

Quantitative MRI in patients with secondary progressive MS treated with monoclonal antibody Campath 1H.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.1

Preliminary evidence from magnetic resonance imaging for reduction in disease activity after lymphocyte depletion in multiple sclerosis.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.1

Stronger association of drug-induced progressive multifocal leukoencephalopathy (PML) with biological immunomodulating agents

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.1

Reversible posterior leukoencephalopathy syndrome after bevacizumab/FOLFIRI regimen for metastatic colon cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.1

Reversible posterior leukoencephalopathy syndrome and bevacizumab.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.1

Increased MRI activity and immune activation in two multiple sclerosis patients treated with the monoclonal anti-tumor necrosis factor antibody cA2.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.1

Adalimumab-associated optic neuritis.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.1

Demyelinating events in rheumatoid arthritis after drug exposures

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.1

Tumor necrosis factor-alpha antagonists and neuropathy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.1

Tumor necrosis factor antagonist mechanisms of action: a comprehensive review

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.1

Guillain-Barré and Miller Fisher syndromes occurring with tumor necrosis factor alpha antagonist therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.1

Long-term course of demyelinating neuropathies occurring during tumor necrosis factor-alpha-blocker therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.1

Chronic inflammatory demyelinating polyneuropathy associated with tumor necrosis factor-alpha antagonists

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.1

Infliximab-associated neuropathy in RA patients--the importance of considering the diagnosis of mononeuritis multiplex

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.1

Acute neuropathy with multiple conduction blocks after TNFalpha monoclonal antibody therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.1

Peripheral neuropathy in patients with inflammatory bowel disease.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.1

Approaches for identifying and defining environmentally associated rheumatic disorders

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.1

Peripheral neuropathy in two patients with rheumatoid arthritis receiving infliximab treatment

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.1

Successful rechallenge with anti-tumor necrosis factor alpha for psoriatic arthritis after development of demyelinating nervous system disease during initial treatment: comment on the article by Mohan et al

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.1

Neuropathy resembling CIDP in patients receiving tumor necrosis factor-alpha blockers

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.1

Lewis-Sumner syndrome associated with infliximab therapy in rheumatoid arthritis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.1

Asymptomatic reactivation of JC virus in patients treated with natalizumab

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.1

Reemergence of PML in natalizumab-treated patients--new cases, same concerns

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.1

Impairment of TNF-receptor-1 signaling but not fas signaling diminishes T-cell apoptosis in myelin oligodendrocyte glycoprotein peptide-induced chronic demyelinating autoimmune encephalomyelitis in mice

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.1

Treatment of progressive multifocal leukoencephalopathy associated with natalizumab.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.1

Safety analyses of adalimumab (HUMIRA) in global clinical trials and US postmarketing surveillance of patients with rheumatoid arthritis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.1

Adalimumab alone and in combination with disease-modifying antirheumatic drugs for the treatment of rheumatoid arthritis in clinical practice: the Research in Active Rheumatoid Arthritis (ReAct) trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.1

Adalimumab safety in global clinical trials of patients with Crohn's disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.1

Demyelination and inhibition of tumor necrosis factor (TNF).

31 March 2020

1 reference

12 December 2020

Alemtuzumab vs. interferon beta-1a in early multiple sclerosis

1 reference

12 December 2020

Anti-tumor necrosis factor-alpha therapy-induced vasculitis: case series.

1 reference

12 December 2020

The polymorphisms of the TNF-α gene in multiple sclerosis?--a meta-analysis.

1 reference

12 December 2020

Sensory neuropathy revealing necrotizing vasculitis during infliximab therapy for rheumatoid arthritis

1 reference

12 December 2020

TNF neutralization in MS: results of a randomized, placebo-controlled multicenter study. The Lenercept Multiple Sclerosis Study Group and The University of British Columbia MS/MRI Analysis Group

1 reference

12 December 2020

Identifiers

DOI

10.1038/NRNEUROL.2011.1

1 reference

24 August 2017

1 reference

PubMed ID

21263460